Ginsenoside 3β-O-Glc-DM (C3DM) suppressed glioma tumor growth by downregulating the EGFR/PI3K/AKT/mTOR signaling pathway and modulating the tumor microenvironment
Authors:
- 11 January 2023
- journal article
- research article
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 460, 116378
Abstract
No abstract availableKeywords
Funding Information
- CAMS Innovation Fund for Medical Sciences (2021-I2M-1-057)
- Chinese Academy of Meteorological Sciences
This publication has 41 references indexed in Scilit:
- Prospective Study of Transcatheter Arterial Chemoembolization (TACE) with Ginsenoside Rg3 versus TACE Alone for the Treatment of Patients with Advanced Hepatocellular CarcinomaRadiology, 2016
- c-MYC inhibition impairs hypoxia response in glioblastoma multiformeOncotarget, 2016
- The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain TumorBrain Pathology, 2015
- Ginsenoside Rh2-B1 stimulates cell proliferation and IFN-γproduction by activating the p38 MAPK and ERK-dependent signaling pathways in CTLL-2 cellsImmunopharmacology and Immunotoxicology, 2013
- c-Myc enhances colon cancer cell-mediated angiogenesis through the regulation of HIF-1αBiochemical and Biophysical Research Communications, 2013
- Modulation of Microenvironment Acidity Reverses Anergy in Human and Murine Tumor-Infiltrating T LymphocytesCancer Research, 2012
- Angiogenesis and invasion in gliomaBrain Tumor Pathology, 2011
- A therapeutic role for targeting c-Myc/Hif-1- dependent signaling pathwaysCell Cycle, 2010
- Oncogenic EGFR Signaling Networks in GliomaScience Signaling, 2009
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001